Abstract P3-11-17: A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients

E Whitacre; E Manahan; W Burak; T Morgan; R An; D Loesch

doi:10.1158/1538-7445.SABCS18-P3-11-17

Abstract P3-11-17: A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients

E Whitacre
, E Manahan
, W Burak
, T Morgan
, R An
, D Loesch

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Research
Volume	79
DOIs	https://doi.org/10.1158/1538-7445.SABCS18-P3-11-17
State	Published - Feb 15 2019

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1158/1538-7445.SABCS18-P3-11-17License: Unspecified

Cite this

@article{be805dd1b36f4d67b782cbc6b6be8ea0,

title = "Abstract P3-11-17: A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients",

author = "E Whitacre and E Manahan and W Burak and T Morgan and R An and D Loesch",

note = "Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas Background: Use of neoadjuvant chemotherapy (NAC) in breast cancer patients has increased significantly over the past decade. The clinical benefits of NAC, including potential to downstage disease, facilitation of breast conserving surgery and use of pathologic response as a prognostic marker, are well established.",

year = "2019",

month = feb,

day = "15",

doi = "10.1158/1538-7445.SABCS18-P3-11-17",

language = "American English",

volume = "79",

journal = "Cancer Research",

issn = "1538-7445",

publisher = "American Association for Cancer Research",

}

TY - JOUR

T1 - Abstract P3-11-17: A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients

AU - Whitacre, E

AU - Manahan, E

AU - Burak, W

AU - Morgan, T

AU - An, R

AU - Loesch, D

N1 - Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas Background: Use of neoadjuvant chemotherapy (NAC) in breast cancer patients has increased significantly over the past decade. The clinical benefits of NAC, including potential to downstage disease, facilitation of breast conserving surgery and use of pathologic response as a prognostic marker, are well established.

PY - 2019/2/15

Y1 - 2019/2/15

UR - https://cancerres.aacrjournals.org/content/79/4_Supplement/P3-11-17

U2 - 10.1158/1538-7445.SABCS18-P3-11-17

DO - 10.1158/1538-7445.SABCS18-P3-11-17

M3 - Article

SN - 1538-7445

VL - 79

JO - Cancer Research

JF - Cancer Research

ER -

Abstract P3-11-17: A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients

Disciplines

Access to Document

Other files and links

Cite this